Addition Therapeutics has successfully raised $106.5 million to further its innovative approach in the competitive arena of gene insertion. This funding is earmarked for the development of its proprietary RNA ‘jumping gene’ therapies, a technology that promises to enhance gene delivery and expression. The startup, which is leveraging groundbreaking research from the University of California, Berkeley, aims to address significant challenges in gene therapy, particularly in terms of efficiency and precision.
The influx of capital not only underscores investor confidence in Addition Therapeutics’ scientific approach but also highlights the growing interest in RNA-based therapies within the biopharmaceutical sector. As the demand for effective gene therapies escalates, this funding positions Addition Therapeutics as a formidable player in the market, potentially accelerating advancements in treatment options for genetic disorders and other diseases.
Use the database as your supply chain compass →
